Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

3 treatments under study, led by Idsmmspecdi 2cbcltests Of Facial Expression Evaluation

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 67/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (1)
Phase 4 (1)

Trial Status

Completed2
Terminated1
Unknown1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT04954729CompletedPrimary

Association of Processing Speed Dysfunction and Brain Functional Abnormality in ECTS

NCT03465566Unknown

Emotion Recognition in Benign Epilepsy of Childhood With Centro-Temporal Spikes (BECTS)

NCT00216567Phase 4CompletedPrimary

Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy

NCT00471744Phase 3TerminatedPrimary

HEAD-Study Optimizing the Treatment of Children With BECTS

Showing all 4 trials

Research Network

Common Treatments

  • Idsmmspecdi 2cbcltests Of Facial Expression Evaluation1
  • Topiramate1
  • Treatment With Levetiracetam Or Sulthiame Over A Sixmonth Period1

Active Sponsors

  • Ludwig-Maximilians - University of Munich1
  • Neuromed IRCCS1
  • Janssen Korea, Ltd., Korea1
  • Second Affiliated Hospital, Zhejiang University, School of Medicine1

Top Investigators

Related Conditions

  • Bects1

Activity Timeline